Hypertrophic Cardiomyopathy (HCM)

1. Topic Overview

Summary

Hypertrophic Cardiomyopathy (HCM) is a genetic cardiac disorder characterised by unexplained left ventricular hypertrophy (wall thickness ≥15 mm, or ≥13 mm with family history of HCM) in the absence of abnormal loading conditions such as hypertension or aortic stenosis. HCM is the most common inherited cardiac disease, with a prevalence of approximately 1 in 500 individuals (0.2%) in the general population. [1] The condition is caused primarily by mutations in genes encoding sarcomeric proteins, with MYBPC3 and MYH7 collectively accounting for approximately 60% of genetically-confirmed cases. [2,3]

HCM represents the leading cause of sudden cardiac death (SCD) in young individuals, including competitive athletes, although the overall annual SCD risk in unselected HCM populations is 0.5-1%. [4,5] The clinical spectrum ranges from asymptomatic individuals identified through family screening to those with severe symptoms of heart failure, atrial fibrillation, stroke, and malignant ventricular arrhythmias. The heterogeneous presentation reflects variable genetic penetrance, allelic diversity, and environmental modifiers. [6]

Contemporary management focuses on three pillars: (1) symptom control through pharmacological and invasive septal reduction therapies, (2) sudden death risk stratification using validated risk calculators and advanced imaging, and (3) cascade genetic screening of first-degree relatives to enable early diagnosis and preventive interventions. [7] The recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor, represents a paradigm shift in targeting the fundamental pathophysiological mechanism of hypercontractility in obstructive HCM. [8,9]

Key Facts

• Definition: Unexplained LV wall thickness ≥15 mm in any myocardial segment (or ≥13 mm with family history/genetic confirmation)
• Prevalence: 1 in 500 (0.2%); most common inherited cardiovascular disease [1]
• Genetic Architecture: Autosomal dominant inheritance with variable penetrance; 40-60% have identifiable sarcomere gene mutations [2,3]
• Common Causal Genes: MYBPC3 (35-40%), MYH7 (25-30%), TNNT2 (5%), TNNI3 (5%) [2,10]
• Sudden Cardiac Death: Leading cause of SCD in young athletes and individuals less than 35 years; overall SCD risk 0.5-1% annually [4,5]
• Obstruction: Left ventricular outflow tract (LVOT) gradient ≥30 mmHg occurs in approximately 70% at rest or with provocation [11]
• Penetrance: Approximately 50% of sarcomere mutation carriers develop diagnostic HCM phenotype over 15 years of follow-up [12]
• Novel Therapy: Mavacamten (cardiac myosin inhibitor) approved 2022; reduces LVOT gradient by 50% and improves functional capacity [8,9]

Clinical Pearls

High-Yield Points:

• Silent Majority: 60-70% of HCM patients are asymptomatic or minimally symptomatic; diagnosis often incidental on echocardiography or family screening
• Dynamic Obstruction: LVOT gradient is physiologically variable; increases with reduced preload (Valsalva, standing, dehydration, vasodilators) and decreases with increased preload/afterload (squatting, beta-blockers)
• Risk Stratification: Use ESC HCM Risk-SCD calculator for 5-year SCD risk estimation; ICD recommended if ≥6% (Class I), consider if 4-6% (Class IIa) [7]
• Exertional Syncope: Red flag symptom requiring urgent evaluation; associated with LVOT obstruction, malignant arrhythmias, or abnormal vasodilator response
• Mavacamten Monitoring: Requires serial echocardiography every 4 weeks during dose titration; risk of excessive LV systolic function reduction and heart failure [8]
• Genetic Cascade Screening: First-degree relatives require clinical screening (ECG, echo) every 3-5 years if mutation-negative; once if specific familial mutation excluded [13]
• Sports Participation: Individualised approach based on 2022 ESC consensus; low-moderate intensity recreational exercise generally safe; competitive sports require careful risk assessment [14]
• Avoid ACE Inhibitors/ARBs: Contraindicated in obstructive HCM due to vasodilation worsening LVOT gradient
• Apical Variant: More common in East Asian populations; giant negative T waves (≥10 mm) in precordial leads; lower SCD risk than septal HCM
• CMR LGE: Extensive late gadolinium enhancement (≥15% LV mass) is independent predictor of SCD and should be incorporated into risk stratification [15]

Why This Matters

HCM exemplifies the paradigm shift in cardiology from symptomatic management to predictive, preventive, and personalized medicine. Despite being a monogenic disorder in many cases, HCM demonstrates remarkable clinical heterogeneity—from asymptomatic carriers to young athletes experiencing sudden death during competition. This variability underscores the critical importance of:

1. Early Detection: Family screening programs enable identification of at-risk individuals before adverse events occur
2. Precision Risk Stratification: Modern risk calculators and advanced imaging (CMR with LGE quantification) allow individualized SCD risk assessment, optimizing ICD implantation decisions
3. Mechanism-Based Therapy: Mavacamten directly addresses hypercontractility, the fundamental pathophysiological abnormality, rather than downstream consequences
4. Lifelong Surveillance: Disease expression evolves over decades; serial reassessment ensures timely intervention for emerging arrhythmias, obstruction, or heart failure

The devastating impact of SCD in previously healthy young individuals, combined with highly effective preventive strategies (ICD therapy in high-risk patients), makes accurate diagnosis and risk stratification an urgent clinical priority.

---

2. Epidemiology

Prevalence and Incidence

Demographics

Age Distribution:

• Median age at diagnosis: 45-50 years (broad range from infancy to elderly)
• Bimodal peaks: adolescence/young adulthood and 5th-6th decades
• Earlier diagnosis in MYH7 mutation carriers vs MYBPC3 (childhood vs middle age) [10]
• Paediatric HCM (< 18 years): distinct entity with higher proportion of syndromic/metabolic causes

Sex Differences:

• Equal genetic prevalence in males and females (autosomal dominant inheritance)
• Males present earlier and with more severe phenotype [6]
• Male sex independent predictor of HCM development in mutation carriers (HR 2.91) [12]
• Higher rates of LVOT obstruction and septal myectomy in males

Ethnic/Geographic Variation:

• Apical HCM variant: 25% of HCM in Japan vs < 5% in Western populations [16]
• Founder mutations: geographically restricted high-penetrance variants (e.g., Norwegian MYBPC3-Gln1061X, Finnish TPM1-Asp175Asn) [17]
• Higher mutation detection rate in European ancestry (50-60%) vs Asian populations (30-40%)

Special Populations:

• Athletes: HCM accounts for 30-40% of SCD in young competitive athletes [5]
• Familial Screening Cohorts: Younger age at diagnosis, higher asymptomatic proportion, better outcomes (lead-time bias)

---

3. Pathophysiology

Molecular Genetics

HCM is fundamentally a disease of the cardiac sarcomere, caused by mutations in genes encoding thick filament, thin filament, and Z-disc proteins. [2,3]

Mutation Characteristics:

• MYBPC3: Predominantly truncating (nonsense, frameshift, splice-site); haploinsufficiency mechanism debated [19]
• MYH7: Predominantly missense; poison peptide/dominant-negative mechanism
• Double Mutations: Present in 3-5% of HCM; associated with earlier onset, greater hypertrophy, worse prognosis [20]
• Variants of Uncertain Significance (VUS): 30-40% of genetic testing results; clinical correlation essential

Genotype-Phenotype Correlations:

• MYBPC3: Later onset (median 50s), incomplete penetrance, milder obstruction [10]
• MYH7: Earlier onset (median 30s-40s), higher penetrance, severe septal hypertrophy [10]
• TNNT2: "Thin-walled hypertrophy" with high arrhythmia risk despite modest LV wall thickness [18]
• Young age at diagnosis and sarcomere mutation status are powerful predictors of adverse outcomes (HF, AF, SCD) [6]

Non-Sarcomeric HCM Phenocopies (exclude before sarcomere gene testing):

• Fabry disease (GLA): corneal verticillata, angiokeratoma, nephropathy
• Danon disease (LAMP2): intellectual disability, skeletal myopathy, pre-excitation
• PRKAG2 syndrome: pre-excitation (WPW), conduction disease
• Mitochondrial disorders: multi-system involvement
• Amyloidosis (TTR, AL): restrictive physiology, low ECG voltage despite thick walls, "sparkling" myocardium

Cellular and Molecular Mechanisms

1. Hypercontractility and Increased Myofilament Ca²⁺ Sensitivity

• Sarcomere mutations increase number of myosin heads in force-generating state [21]
• Enhanced actin-myosin cross-bridge formation → increased contractile force
• Elevated myofilament Ca²⁺ sensitivity → prolonged systole, impaired relaxation
• Mavacamten mechanism: allosteric myosin inhibitor stabilizes super-relaxed state, reducing available myosin heads [8]

2. Myocyte Hypertrophy

• Compensatory response to sarcomere dysfunction
• Activation of hypertrophic signalling pathways (calcineurin, mTOR, MAPK)
• Cardiomyocyte cross-sectional area increased 2-3 fold
• Predominantly asymmetric septal hypertrophy (70% of cases)

3. Myocyte Disarray

• Pathognomonic histological feature (present in 50% of myocardium in HCM)
• Loss of normal parallel myocyte alignment
• "Swirling" pattern at cellular level
• Substrate for re-entrant ventricular arrhythmias

4. Interstitial and Replacement Fibrosis

• Myocyte death (apoptosis/necrosis) → replacement fibrosis (focal scarring)
• Interstitial fibrosis (perivascular, diffuse) from ischaemia, inflammation
• Visible as late gadolinium enhancement (LGE) on cardiac MRI
• Extent of LGE correlates with SCD risk, heart failure progression [15]

5. Microvascular Ischaemia

• Supply-demand mismatch: increased myocardial mass, elevated wall stress, increased O₂ demand
• Impaired coronary flow reserve despite normal epicardial coronaries
• Thickened arteriolar walls, luminal narrowing (medial hypertrophy)
• Manifests as angina with normal coronary angiography

6. Diastolic Dysfunction

• Impaired active relaxation (energy-dependent SERCA2a-mediated Ca²⁺ reuptake)
• Reduced compliance (stiff myocardium from hypertrophy, fibrosis)
• Elevated LV filling pressures → dyspnoea, pulmonary congestion
• Normal or hyperdynamic systolic function (EF 70-80% typical)

Haemodynamic Consequences

Left Ventricular Outflow Tract (LVOT) Obstruction:

Present in 70% of HCM patients (rest or provocation); defined as peak gradient ≥30 mmHg [11]

Mechanism:

1. Anatomical substrate: Asymmetric septal hypertrophy narrows LVOT
2. Systolic anterior motion (SAM): Mitral valve anterior leaflet drawn into LVOT during systole
3. Venturi effect: High-velocity flow through narrowed LVOT creates negative pressure, pulling mitral leaflet forward
4. Mitral-septal contact: Causes mid-to-late systolic obstruction and mitral regurgitation

Dynamic Nature:

• Increased by: ↓ Preload (Valsalva, standing, dehydration, nitrates, diuretics), ↑ Contractility (exercise, inotropes), ↓ Afterload (vasodilators)
• Decreased by: ↑ Preload (squatting, leg raise, fluids), ↓ Contractility (beta-blockers, CCBs), ↑ Afterload (handgrip, phenylephrine)

Clinical Consequences:

• Dyspnoea: Elevated LV filling pressures from diastolic dysfunction and functional mitral regurgitation
• Angina: Increased wall stress, myocardial O₂ demand
• Syncope: Inadequate cardiac output during exertion; baroreceptor-mediated reflex hypotension
• Mitral regurgitation: Posteriorly-directed eccentric jet (SAM mechanism) vs central jet (intrinsic mitral pathology)

---

4. Clinical Presentation

Symptom Spectrum

Asymptomatic (60-70% at diagnosis):

• Incidental echocardiographic finding (murmur detected on routine examination)
• Family screening detection (cascade testing of relatives)
• Pre-participation sports screening (ECG/echo abnormalities)
• Normal life expectancy possible with appropriate surveillance

Symptomatic Presentations:

Red Flag Symptoms (High SCD Risk):

• Exertional syncope: Suggests inadequate cardiac output or malignant arrhythmia
• Recurrent syncope: Multiple episodes increase concern
• Palpitations with syncope: Possible VT/VF
• Chest pain with syncope: Ischaemia-triggered arrhythmia
• Family history of SCD: Shared genetic substrate

Heart Failure Progression:

• Early: Diastolic HF with preserved EF (80% of symptomatic patients)
• Advanced: "Burnt-out" HCM with systolic dysfunction (EF < 50% in 5-10% over time)
• End-stage: Dilated, thin-walled LV; consider cardiac transplantation

Atrial Fibrillation:

• Prevalence: 20-30% over lifetime; increases with age and LA enlargement
• All HCM patients with AF require anticoagulation (high stroke risk regardless of CHA₂DS₂-VASc) [7]
• Poorly tolerated: Loss of atrial kick, rapid ventricular rate → acute decompensation

Sudden Cardiac Death:

• Presenting manifestation in 10-20% of HCM (often first sign in young athletes)
• Mechanism: Ventricular fibrillation from monomorphic VT degenerating
• Triggers: Intense physical exertion, competitive sports

---

5. Clinical Examination

General Inspection

• Usually well-appearing at rest
• Signs of heart failure (elevated JVP, peripheral oedema) in advanced cases
• Syndromic features (if HCM phenocopy): Fabry angiokeratoma, Danon facies

Cardiovascular Examination

Pulse:

• Bifid "spike-and-dome" carotid pulse (Brockenbrough-Braunwald sign)
  • "Initial peak: Rapid early systolic ejection"
  • "Mid-systolic dip: LVOT obstruction"
  • "Second peak: Late systolic flow"
• Brisk, jerky upstroke (vs slow-rising pulse of aortic stenosis)

Jugular Venous Pressure:

• Prominent 'a' wave: Reduced RV compliance (septal involvement), pulmonary hypertension
• Normal or mildly elevated in compensated disease

Precordial Palpation:

• Apical impulse: Sustained, forceful, may be displaced laterally
• Double apical impulse: Palpable atrial contraction (forceful 'a' wave)
• Parasternal heave: RV hypertrophy (septal involvement)

Auscultation:

Provocative Manoeuvres:

Differentiating HCM from Aortic Stenosis:

---

6. Investigations

Electrocardiography (ECG)

Abnormal in 90-95% of HCM cases (normal ECG does not exclude diagnosis)

Special Patterns:

• Apical HCM: Giant negative T waves (≥10 mm depth) in V3-V5 [22]
• Mid-cavity obstruction: Mid-precordial T inversion
• Non-obstructive HCM: Often less voltage, fewer repolarization abnormalities

Ambulatory ECG Monitoring (24-48hr Holter)

Indications:

• Initial evaluation of all HCM patients
• Palpitations, syncope, presyncope
• Reassessment every 1-2 years (detect NSVT, AF)

Key Findings:

Echocardiography

Gold standard for HCM diagnosis [7]

Diagnostic Criteria:

• LV wall thickness ≥15 mm in any segment (anterior septum most common) in absence of loading conditions
• ≥13 mm acceptable if: family history of HCM, positive genetic test, or supporting features
• Paediatric: Z-score ≥2 for age/BSA

Essential Measurements:

Patterns of Hypertrophy:

Provocative Testing for Latent LVOT Obstruction:

• Valsalva manoeuvre: Strain phase during continuous-wave Doppler
• Exercise echocardiography: Treadmill or supine bicycle; gradient measured immediately post-exercise
• Physiological saline contrast: Visualize SAM if acoustic windows poor
• Amyl nitrite inhalation: Historic; rapid vasodilation provokes obstruction

Diastolic Function Assessment:

• Mitral inflow (E/A ratio): Often E/A < 1 (impaired relaxation) or 2 (restrictive)
• Tissue Doppler (e'): Reduced septal/lateral e' velocity (< 8 cm/s)
• E/e' ratio: Elevated (14); estimates LV filling pressure
• LA volume index: Best correlate of chronic diastolic dysfunction

Cardiac Magnetic Resonance Imaging (CMR)

Indications:

• Inconclusive echocardiography (poor acoustic windows, atypical patterns)
• Apical/mid-cavity variants (echo may underestimate apical thickness)
• SCD risk stratification (LGE quantification) [15]
• Pre-septal reduction therapy planning (anatomy mapping)
• Suspected phenocopies (infiltration, storage disease)

Advantages over Echocardiography:

• Superior spatial resolution (1-2 mm slice thickness)
• Unrestricted field of view (entire LV visualized)
• Tissue characterization (T1/T2 mapping, LGE)
• Accurate mass quantification

Key CMR Findings:

Late Gadolinium Enhancement (LGE):

• Present in 50-80% of HCM patients
• Patterns: Patchy mid-wall (RV insertion points common), confluent
• Quantification: % of LV mass with LGE
  • "≥15% LV mass: Major SCD risk factor (independent of other variables) [15]"
  • "5-15%: Intermediate risk; should inform ICD decisions"
  • "< 5%: Lower risk"
• Correlates with: adverse remodelling, progression to systolic dysfunction, ventricular arrhythmias, heart failure, SCD

CMR Phenocopies (Help Differentiate):

• Amyloidosis: Global transmural LGE, elevated native T1, difficulty nulling blood pool
• Fabry: Basal inferolateral LGE (classic pattern), low native T1
• Athlete's heart: Regression with deconditioning, no LGE, normal diastolic function

Genetic Testing

Indications (2023 ESC Guidelines) [7]:

• All patients with HCM (unless phenocopy suspected)
• Enables cascade screening of relatives
• Informs prognosis (sarcomere mutation carriers have worse outcomes) [6]

Testing Strategy:

• Sarcomere gene panel: MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, TNNC1
• Extended panel (if syndromic features): GLA (Fabry), LAMP2 (Danon), PRKAG2
• Whole exome sequencing: If strong family history but negative panel

Result Interpretation:

Yield by Population:

• Familial HCM: 60-70%
• Sporadic HCM: 30-40%
• Paediatric HCM: 40% (higher if exclude metabolic causes)

Cascade Screening Protocol:

• Mutation-positive family: Test relatives for specific familial mutation
  • "Negative: Discharge (rare surveillance)"
  • "Positive: Clinical screening (ECG/echo) q12-18mo (children/adolescents), q3-5y (adults)"
• Mutation-negative family: Clinical screening all first-degree relatives q3-5y

Prognostic Value:

• Sarcomere mutation carriers: 2-fold higher risk adverse outcomes (HF, AF, SCD) vs mutation-negative [6]
• Young age at diagnosis + mutation positive: 77% cumulative composite endpoint by age 60 [6]
• TNNT2 mutations: High SCD risk despite mild hypertrophy [18]

Exercise Testing

Indications:

• Functional capacity assessment (peak VO₂)
• Exercise-induced LVOT gradient (if < 30 mmHg at rest)
• Blood pressure response to exercise (SCD risk stratification)
• Sports participation counselling
• Symptomatic status verification (discrepancy with reported symptoms)

Protocol:

• Standard Bruce or ramp protocol
• Continuous ECG monitoring
• Serial BP measurements q2 minutes
• Echocardiography immediately post-exercise (LVOT gradient)

Key Findings:

Contraindications:

• Decompensated heart failure
• Severe symptomatic LVOT obstruction
• Recent syncope (until evaluated)

Invasive Testing

Cardiac Catheterization:

Rarely required for HCM diagnosis; reserved for specific scenarios

Indications:

• Angina with intermediate pre-test CAD probability (exclude concomitant CAD before attributing to HCM)
• Pre-septal reduction therapy assessment (anatomy, gradient confirmation)
• Alcohol septal ablation procedure
• Heart failure with HCM and suspected CAD

Haemodynamic Findings:

• Elevated LVEDP (diastolic dysfunction)
• LVOT gradient (pull-back gradient from LV apex to aorta)
• Brockenbrough-Braunwald sign: Post-PVC ↑ aortic pulse pressure but ↓ LVOT gradient (vs AS: ↑ both)
• Normal coronary arteries (unless coexistent atherosclerosis)
• "Myocardial bridging" (systolic compression of LAD): present in 20-30%; usually benign

Coronary Angiography:

• Identify septal perforator anatomy pre-alcohol ablation
• Exclude CAD in angina patients

---

7. Classification

Anatomical Classification (by Obstruction)

Mid-Cavity Obstruction:

• Variant with mid-ventricular obliteration (papillary muscle hypertrophy, apposition)
• Associated with apical aneurysm formation (10-15% of mid-cavity HCM)
• Higher thromboembolic risk (apical thrombus formation)

Morphological Classification

Aetiological Classification

Primary (Sarcomeric) HCM:

• Genetic mutations in sarcomere protein genes
• Accounts for 40-60% of phenotypic HCM
• Autosomal dominant inheritance

HCM Phenocopies (Secondary):

• Fabry Disease (GLA): α-galactosidase A deficiency; enzyme replacement available
• Danon Disease (LAMP2): Lysosomal storage disorder; severe, early-onset
• PRKAG2 Syndrome: AMP kinase mutation; pre-excitation, conduction disease
• Mitochondrial Disorders: Maternal inheritance; multi-system
• Amyloidosis (TTR, AL): Infiltrative; restrictive physiology; tafamidis (TTR)
• Noonan Syndrome: RASopathy; dysmorphic features, pulmonary stenosis

Acquired/Secondary Hypertrophy (Not True HCM):

• Hypertensive heart disease
• Aortic stenosis
• Athlete's heart
• Amyloidosis (listed above as phenocopy)

---

8. Management

Contemporary HCM management is structured around three pillars: symptomatic treatment, SCD risk stratification, and genetic counselling/family screening. [7]

Step 1: Sudden Cardiac Death (SCD) Risk Stratification

ESC HCM Risk-SCD Calculator (5-year risk estimate) [7,23]:

Variables in Model:

1. Age (years)
2. Maximum LV wall thickness (mm)
3. Left atrial diameter (mm)
4. Maximum LVOT gradient (mmHg)
5. Family history of SCD (yes/no)
6. Non-sustained VT on Holter (yes/no)
7. Unexplained syncope (yes/no)

Risk Categories and ICD Recommendations:

Additional High-Risk Features (Not in Calculator):

• Massive LVH: Maximum wall thickness ≥30 mm (especially if < 30 years old)
• LV apical aneurysm: 5-10% lifetime risk; strong SCD predictor [24]
• Extensive LGE: ≥15% of LV mass on CMR [15]
• End-stage HCM: EF < 50% (systolic dysfunction)
• Marked LVOT obstruction: Gradient ≥100 mmHg

Special Populations:

2024 AHA/ACC Guidelines (alternative risk model):

• More granular Class IIa vs IIb stratification
• Includes exercise BP response, LGE
• May classify more intermediate-risk patients for ICD consideration

ICD Complications in HCM:

• Appropriate shocks: 3-5% per year in high-risk patients (life-saving)
• Inappropriate shocks: 10-15% over 5 years (AF, lead fracture)
• Lead complications: Higher in young patients (decades of device therapy)
• Subcutaneous ICD (S-ICD): Consider if no pacing/ATP needs; avoid lead complications

Step 2: Symptom Management

A. Non-Obstructive HCM or Mild Obstruction (< 50 mmHg)

Goal: Improve diastolic function, reduce heart rate, allow adequate filling time

B. Symptomatic Obstructive HCM (Gradient ≥50 mmHg + Symptoms)

Stepwise Pharmacological Approach:

Step 1: Beta-Blockers

• First-line: Non-vasodilating beta-blockers (bisoprolol, metoprolol, propranolol)
• Target: Resting HR 60-65 bpm; maximal tolerated dose
• Efficacy: Reduce symptoms in 60-70% of patients
• Mechanism: Negative inotropy (↓ contractility), ↓ HR (↑ filling time)

Step 2: Add Disopyramide (if inadequate response to beta-blocker alone)

• Class Ia antiarrhythmic with negative inotropic effects
• Dosing: 300-600 mg/day (divided doses)
• Mechanism: Directly reduces SAM and LVOT gradient
• Efficacy: Additional 20-30% reduction in gradient when added to beta-blocker [26]
• Side effects: Anticholinergic (dry mouth, urinary retention, constipation), QT prolongation
• Monitoring: Serial ECGs (QTc < 500 ms), LFTs

Step 3: Mavacamten (Novel Cardiac Myosin Inhibitor)

Mechanism: Allosteric inhibitor of cardiac myosin ATPase; stabilizes super-relaxed state, reducing number of myosin heads available for actin binding [8,21]

Indications (FDA/EMA approved 2022):

• Symptomatic obstructive HCM (NYHA II-III)
• LVOT gradient ≥50 mmHg
• Inadequate response to maximally tolerated medical therapy
• Alternative to septal reduction therapy or patient preference

Key Trials:

• EXPLORER-HCM (2020) [8]: Mavacamten vs placebo in 251 obstructive HCM patients

  • "Primary endpoint: ↑ peak VO₂ (+1.4 mL/kg/min, p< 0.001)"
  • "LVOT gradient: 47% reduction (vs 10% placebo)"
  • "NYHA class improvement: 65% vs 31%"
  • "Composite functional endpoint: 37% vs 17% (p< 0.001)"

• VALOR-HCM (2022) [9]: Mavacamten vs placebo in 112 patients eligible for septal reduction

  • "Primary endpoint: Avoidance of septal reduction procedure (74% vs 46%, p< 0.001)"
  • Sustained gradient reduction and symptom improvement at 56 weeks

Dosing and Monitoring:

• Starting dose: 5 mg daily (2.5 mg if on moderate CYP2C19 inhibitors)
• Titration: Every 4 weeks based on echo LVOT gradient and LVEF
• Target: LVOT gradient < 30 mmHg, maintain LVEF ≥50%
• Maximum: 15 mg daily
• Monitoring: Echocardiography every 4 weeks during titration, then q12 weeks

Contraindications and Precautions:

• Absolute: LVEF < 55%, NYHA IV, severe hepatic impairment
• Drug interactions: Strong CYP2C19/3A4 inhibitors (↑ mavacamten levels); avoid or dose-adjust
• Pregnancy: Contraindicated (teratogenic in animals); effective contraception required
• Risk: Excessive LV systolic function reduction (10-15% develop LVEF < 50%); reversible with dose reduction/discontinuation

C. Refractory Symptomatic Obstruction (Failed Maximal Medical Therapy)

Septal Reduction Therapy Indications:

• NYHA III-IV symptoms despite maximal medical therapy
• LVOT gradient ≥50 mmHg at rest or with provocation
• Septal thickness ≥15 mm (procedural feasibility)

Option 1: Surgical Septal Myectomy (Morrow Procedure)

Technique:

• Transaortic resection of basal septum (10-15 g myocardium)
• Extended myectomy: Extends to papillary muscles if needed
• Concomitant mitral valve repair/replacement if intrinsic pathology

Outcomes (experienced centres):

• Operative mortality: < 1% (volume-dependent; centres 25 cases/year) [27]
• Gradient reduction: 90% achieve < 30 mmHg post-operatively
• Symptom improvement: 85-90% sustained NYHA I-II at 5-10 years
• Durability: Excellent long-term (10-20 year) results
• Survival: Comparable to general population if uncomplicated

Complications:

• Complete heart block requiring PPM: 5-10%
• VSD (iatrogenic): < 1%
• Aortic regurgitation: < 5%
• Mitral valve injury: Rare

Advantages:

• Most durable and definitive treatment
• Can address concomitant mitral pathology
• Reproducible results in experienced hands

Option 2: Alcohol Septal Ablation (ASA)

Technique:

• Percutaneous injection of 1-3 mL absolute alcohol into septal perforator artery
• Creates controlled myocardial infarction (MI) of basal septum
• Scar formation over 3-6 months → gradient reduction

Patient Selection:

• Older patients (50-65 years) or high surgical risk
• Suitable septal perforator anatomy (angiography/contrast echo)
• No concomitant cardiac surgery needs (MVR, CABG)

Outcomes:

• Procedural success: 80-90% achieve gradient < 30 mmHg (may require repeat)
• Symptom improvement: 70-80% sustained NYHA I-II
• Durability: Good 5-10 year results; ~10% require repeat procedure

Complications:

• Complete heart block requiring PPM: 10-20% (higher than myectomy)
• Unintended MI: Collateral alcohol flow to unintended territories (< 5%)
• Ventricular arrhythmias: Peri-procedural VT/VF (< 5%; transient scar-related)
• Mortality: 1-2% (30-day)

Choosing Between Myectomy and ASA:

Post-Septal Reduction Care:

• Re-assess SCD risk (not eliminated by gradient reduction)
• Continue ICD if previously indicated
• Monitor for heart block (may develop late)

Step 3: Atrial Fibrillation Management

All HCM patients with AF require anticoagulation (regardless of CHA₂DS₂-VASc score) [7]

Anticoagulation:

• Options: Warfarin (INR 2-3), DOACs (apixaban, rivaroxaban, edoxaban, dabigatran)
• DOACs: Preferred (easier, no monitoring) unless contraindicated (mechanical valve, severe renal impairment)
• Duration: Lifelong (high stroke risk persists)

Rate vs Rhythm Control:

• Rate control: First-line if well-tolerated

  • Beta-blockers (already on for HCM)
  • Add digoxin, diltiazem if inadequate
  • Target HR < 100 bpm rest, < 120 bpm with exertion

• Rhythm control: Consider if:

  • Poorly tolerated (haemodynamic compromise)
  • Paroxysmal AF with frequent symptomatic episodes
  • Young patient preference

Cardioversion:

• TOE-guided (exclude LA thrombus) or 3-week therapeutic anticoagulation pre-cardioversion
• Continue anticoagulation lifelong post-cardioversion (high recurrence risk)

Catheter Ablation:

• Pulmonary vein isolation (PVI) if symptomatic paroxysmal AF refractory to antiarrhythmics
• Success rates lower than in non-HCM AF (50-70% vs 70-80%)
• Does NOT obviate need for anticoagulation

Step 4: Heart Failure Management

Preserved EF (HFpEF) - Most HCM:

• Beta-blockers, verapamil (as above)
• Diuretics: Cautious use (preload-dependent; low-dose furosemide 20-40 mg PRN)
• Avoid aggressive diuresis (↓ preload → ↑ LVOT obstruction)

Reduced EF (HFrEF) - End-Stage HCM:

• Transition to guideline-directed HFrEF therapy:
  • ACE-I/ARB, beta-blockers, MRA, SGLT2i (standard HF therapy now safe with no obstruction)
• ICD (if not already present; primary prevention if EF ≤35%)
• Cardiac resynchronisation therapy (CRT): If LBBB, QRS ≥130 ms
• Cardiac transplantation: Refractory NYHA IV, EF < 30%, no contraindications
  • Excellent post-transplant survival (HCM recipients have better outcomes than ischaemic cardiomyopathy)

Step 5: Genetic Counselling and Cascade Family Screening

Genetic Testing of Proband:

• Offer to all HCM patients [7]
• Sarcomere gene panel (8-9 core genes)
• Yield: 40-60%

Cascade Screening Protocol:

If Pathogenic Mutation Identified:

• Test all first-degree relatives (parents, siblings, children) for specific mutation
  • "Negative: Reassure; discharge (no HCM risk from this gene)"
  • "Positive: Enter clinical surveillance programme"

If No Mutation Identified (Gene-Negative Family):

• Clinical screening of all first-degree relatives
  • "Frequency: Every 3-5 years (adults), every 12-18 months (children/adolescents to age 21)"
  • "Tests: ECG, echocardiography"
  • "Duration: Lifelong (late penetrance possible)"

Mutation-Positive, Phenotype-Negative Individuals:

• Annual clinical review (ECG, echo)
• Repeat CMR every 2-3 years (detect subclinical LVH earlier than echo)
• No restrictions on lifestyle/occupation while phenotype-negative
• No ICD indicated until diagnostic HCM develops

Step 6: Lifestyle and Activity Recommendations

Exercise and Sports Participation (2022 ESC Consensus) [14]:

Paradigm Shift: From blanket restriction to individualised, shared decision-making approach

Competitive Sports:

• Contraindicated: Severe symptoms (NYHA III-IV), high SCD risk, recent cardiac arrest/sustained VT
• Shared decision-making: Asymptomatic or mildly symptomatic (NYHA I-II), low-intermediate SCD risk
  • "Factors: Patient preference, sport type/intensity, SCD risk profile, psychosocial impact"
  • Requires informed consent, annual reassessment

Recreational Exercise:

• Encouraged: Low-moderate intensity (walking, cycling, swimming, golf)
• Benefits: Cardiovascular fitness, quality of life, mental health
• Caution: Avoid extreme exertion, competitive intensity, dehydration

Occupational Considerations:

• Commercial driving: Usually restricted if ICD, syncope, high SCD risk
• High-risk occupations (pilot, firefighter): Case-by-case; usually restricted

Pregnancy:

• Generally well-tolerated (maternal mortality < 1%)
• Higher risk if: Symptomatic (NYHA III-IV), severe LVOT obstruction, prior arrhythmias
• Management: Multidisciplinary (cardiology, obstetrics, anaesthesia)
  • Continue beta-blockers (safe in pregnancy)
  • Avoid dehydration, hypotension during labour (maintain preload)
  • Vaginal delivery preferred; CS for obstetric indications
  • Epidural safe; avoid spinal (rapid vasodilation)

Other Lifestyle:

• Hydration: Maintain adequate fluid intake (avoid ↓ preload)
• Vasodilators: Avoid (nitrates, PDE5 inhibitors if obstructive)
• Alcohol: Moderate; can cause dehydration, arrhythmias

---

9. Complications

Endocarditis Prophylaxis (2023 ESC) [28]:

• High-risk HCM: Previous IE, prosthetic material (post-myectomy patch), unrepaired cyanotic CHD
• Procedures: Dental (gingival manipulation), respiratory (biopsy), infected skin procedures
• Regimen: Amoxicillin 2 g PO 30-60 min pre-procedure (or clindamycin 600 mg if penicillin allergic)

---

10. Prognosis

Survival

Contemporary Era (with modern management):

• Overall annual mortality: 0.5-1% [5]
• Age-matched general population: Near-normal life expectancy if low SCD risk, asymptomatic
• High-risk patients with ICD: Appropriate shocks in 3-5%/year; life-saving

Mortality by Phenotype:

Prognostic Factors

Favourable Prognosis:

• Asymptomatic or NYHA I
• Non-obstructive
• No major SCD risk factors (ESC score < 4%)
• Minimal LGE (< 5% LV mass)
• No family history of SCD
• Older age at diagnosis (60 years)
• Mutation-negative

Adverse Prognosis:

Lifetime Disease Burden:

• 77% of patients diagnosed < 40 years reach composite endpoint (HF, AF, SCD, ICD shock) by age 60 [6]
• Atrial fibrillation and heart failure are most prevalent long-term adverse events (emerging years after diagnosis)
• SCD risk persists throughout life but highest in young patients (< 30 years)

Effect of Interventions

ICD Therapy:

• Appropriate shocks: 3-5% per year in high-risk patients (10-20% over 5 years)
• Converts fatal VF to shock with survival
• Does NOT prevent SCD substrate (fibrosis, arrhythmias continue)

Septal Reduction (Myectomy/ASA):

• Improves symptoms, functional capacity, quality of life
• Does NOT reduce SCD risk (ICD decisions independent of gradient reduction)
• Long-term survival comparable to general population in low-SCD-risk patients post-myectomy

Mavacamten:

• Sustained gradient reduction and symptom improvement to 3 years (EXPLORER-HCM extension)
• Unknown effect on SCD risk (trial not powered; short follow-up)
• Avoids septal reduction procedures in 74% of eligible patients (VALOR-HCM) [9]

---

11. Evidence and Guidelines

Key Guidelines

Landmark Clinical Trials

Mavacamten (Cardiac Myosin Inhibitor):

EXPLORER-HCM (2020) [8]

• Design: Phase 3, randomised, double-blind, placebo-controlled
• Population: 251 symptomatic obstructive HCM (NYHA II-III, LVOT ≥50 mmHg)
• Intervention: Mavacamten vs placebo × 30 weeks
• Primary Endpoint: ≥1.5 mL/kg/min increase in peak VO₂ AND ≥1 NYHA class improvement, OR ≥3.0 mL/kg/min increase in peak VO₂
• Results:
  • "Primary endpoint: 37% vs 17% (p< 0.001)"
  • "Mean VO₂ increase: +1.4 mL/kg/min (p< 0.001)"
  • "LVOT gradient reduction: -36 mmHg (-47%) vs -10 mmHg (-10%)"
  • "Post-exercise gradient < 30 mmHg: 60% vs 13%"
  • "KCCQ improvement: +9.1 points vs -0.6"
• Conclusion: Mavacamten significantly improved exercise capacity, symptoms, and LVOT obstruction

VALOR-HCM (2022) [9]

• Design: Phase 3, randomised, double-blind, placebo-controlled
• Population: 112 symptomatic obstructive HCM eligible for septal reduction therapy
• Intervention: Mavacamten vs placebo × 16 weeks (primary), extension to 56 weeks
• Primary Endpoint: Decision to proceed with septal reduction therapy at week 16
• Results:
  • "Septal reduction needed: 18% (mavacamten) vs 77% (placebo), p< 0.001"
  • 74% avoided septal reduction with mavacamten
  • "Symptom improvement: NYHA I-II 83% vs 36%"
  • "Gradient reduction: -57 mmHg vs -17 mmHg"
  • Sustained effects at 56 weeks
• Conclusion: Mavacamten eliminated need for septal reduction in majority of eligible patients

Aficamten (Next-Generation Myosin Inhibitor):

SEQUOIA-HCM (2023) [29]

• Design: Phase 3, randomised, placebo-controlled
• Population: 282 symptomatic obstructive HCM
• Intervention: Aficamten (oral daily) vs placebo × 24 weeks
• Results:
  • "Resting LVOT gradient < 30 mmHg AND ≥1 NYHA class improvement: 69% vs 23% (p< 0.001)"
  • "Valsalva gradient reduction: -49 mmHg vs -8 mmHg"
  • Superior symptom improvement vs placebo
• Conclusion: Second cardiac myosin inhibitor validated; alternative to mavacamten (pending regulatory approval)

Genetic and Outcomes Studies

SHaRe Registry (2018) [6]

• Population: 4,591 HCM patients (2,763 genotyped), 24,791 patient-years follow-up
• Key Findings:
  • "Sarcomere mutation carriers: 2-fold ↑ risk adverse outcomes (HF, AF, SCD, transplant) vs mutation-negative"
  • Age at diagnosis < 40 y: 77% cumulative adverse events by age 60 (vs 32% by age 70 if diagnosed 60y)
  • "Young HCM patients (20-29y): 4-fold ↑ mortality vs age-matched general population"
  • "Atrial fibrillation and HF: most prevalent long-term complications (emerge years post-diagnosis)"
• Conclusion: Young age and sarcomere mutation are powerful predictors; need for lifelong surveillance and disease-modifying therapies

Penetrance Study (2020) [12]

• Population: 285 sarcomere mutation carriers without diagnostic HCM at baseline
• Follow-up: Median 8 years
• Key Findings:
  • 30% developed HCM over median 8-year follow-up
  • "Estimated penetrance: 46% (95% CI 38-54%) at 15 years"
  • "Predictors of HCM development: Male sex (HR 2.91), abnormal ECG (HR 4.02)"
  • "TNNI3 mutations: Lowest penetrance (HR 0.19 vs MYBPC3)"
  • CMR detected HCM in 32% of echo-negative patients
• Conclusion: ~50% of mutation carriers develop diagnostic HCM over 15 years; CMR enhances detection

CMR and LGE Risk Stratification (2023) [15]

• Population: 774 HCM patients with CMR, followed 7.4 years
• Endpoints: SCD (cardiac arrest, appropriate ICD shock, SCD)
• Key Findings:
  • "Extensive LGE (≥15% LV mass): 7-fold ↑ SCD risk (multivariable-adjusted)"
  • "LGE 5-15%: Intermediate risk (significantly worse than < 5%)"
  • LGE improves risk stratification within ESC ICD-COR classes II and III
  • 2022 ESC model C-statistic: 0.78 (vs 0.64 for 2014 ESC model)
• Conclusion: LGE should be incorporated into SCD risk stratification; 2022 ESC model superior

Surgical Outcomes

Multi-Centre Myectomy Registry [27]

• Population: 3,000 patients undergoing septal myectomy (1960s-2010s)
• Key Findings:
  • "Operative mortality: < 1% in experienced centres (50 cases/year); 2-3% in low-volume"
  • "Long-term survival: Similar to age/sex-matched general population if low SCD risk"
  • "Gradient elimination: 90% achieve < 30 mmHg"
  • "Complete heart block: 5-10% (lower in recent era)"
  • "Reoperation rate: < 2% at 10 years"
• Conclusion: Septal myectomy is safe, effective, durable in experienced centres

---

12. Patient/Layperson Explanation

What is Hypertrophic Cardiomyopathy (HCM)?

Hypertrophic cardiomyopathy is a condition where the heart muscle becomes abnormally thick (hypertrophied), especially the wall separating the two lower chambers (the septum). This thickening is not caused by high blood pressure or other conditions—it is usually inherited through your genes.

The thickened muscle can make it harder for your heart to pump blood efficiently. In some people, the thickened muscle narrows the path blood takes as it leaves the heart (called an "obstruction"), which can cause symptoms like breathlessness, chest pain, and dizziness.

How Common Is It?

HCM affects about 1 in 500 people, making it the most common inherited heart condition. Many people with HCM live normal lives without symptoms, while others experience breathlessness or other issues. In rare cases, HCM can lead to serious heart rhythm problems.

Is It Dangerous?

For most people with HCM, the outlook is good with proper monitoring and treatment. However, a small number of people are at higher risk of dangerous heart rhythms (arrhythmias) that can be life-threatening. That's why careful assessment of your individual risk is so important.

Your doctor will use information about your symptoms, heart scans, genetic tests, and family history to work out your risk level. If you are at higher risk, treatments like medications or a small device (ICD - implantable cardioverter defibrillator) can protect you.

What Symptoms Might I Experience?

Many people have no symptoms and only find out they have HCM through family screening or a routine check-up.

If symptoms occur, they may include:

• Breathlessness, especially during exercise
• Chest pain or discomfort
• Palpitations (awareness of your heartbeat)
• Dizziness or fainting (especially during exercise—this is an important warning sign to report to your doctor immediately)
• Fatigue

How Is HCM Diagnosed?

Your doctor will:

1. Ask about your symptoms and family history (HCM runs in families)
2. Examine you (listening for heart murmurs)
3. Order tests:
   • ECG (heart tracing): Checks your heart's electrical activity
   • Echocardiogram (heart ultrasound): Measures how thick your heart muscle is
   • Cardiac MRI scan: Provides detailed pictures of your heart
   • Genetic test (blood test): Looks for gene changes that cause HCM; helps with family screening

What Treatments Are Available?

Treatment depends on your symptoms and risk level:

1. Monitoring Only

• Many people need no treatment beyond regular check-ups
• Yearly heart scans and reviews

2. Medications

• Beta-blockers (e.g., bisoprolol, metoprolol): Slow your heart rate, improve symptoms
• Calcium channel blockers (e.g., verapamil): Alternative if beta-blockers don't suit you
• Disopyramide: Reduces obstruction if first-line drugs don't help enough
• Mavacamten (new medication): Directly targets the heart muscle problem; very effective for obstruction

3. Procedures (for severe obstruction not controlled by medication)

• Septal myectomy: Surgery to remove some of the thickened muscle
• Alcohol septal ablation: Injection to shrink part of the thickened muscle (less invasive)

4. ICD (Implantable Cardioverter Defibrillator)

• Small device implanted under your skin (like a pacemaker)
• Monitors your heart rhythm constantly
• Delivers a life-saving shock if a dangerous rhythm occurs
• Recommended if you are at higher risk of sudden cardiac arrest

Can I Exercise?

Yes—but with guidance. Advice about exercise has changed in recent years:

• Light to moderate recreational exercise (walking, swimming, cycling, golf) is usually safe and encouraged
• Competitive or very intense sports: Requires individual assessment with your cardiologist
• Your doctor will advise based on your specific HCM features, symptoms, and risk profile

Always avoid:

• Becoming dehydrated (drink plenty of fluids)
• Extreme exertion without medical clearance

Should My Family Be Tested?

Yes. HCM is inherited (runs in families). Each of your first-degree relatives (parents, siblings, children) has a 50% chance of inheriting the genetic change that caused your HCM.

Family screening involves:

• Genetic test (if a gene change is found in you): Your relatives can have a simple blood test to see if they inherited the same gene change
• Heart checks (ECG and echocardiogram): Repeated every few years to check if HCM is developing

Early detection in relatives allows for monitoring and treatment before complications occur.

Can I Have Children?

Yes. Women with HCM usually tolerate pregnancy well, though it requires specialist care (cardiology and obstetrics working together).

Important points:

• Each child has a 50% chance of inheriting the genetic change
• Your baby can be tested (usually after birth or later in childhood)
• Genetic counselling is available to discuss options

What About Work and Lifestyle?

• Most people with HCM can work normally
• Certain high-risk jobs (e.g., commercial driving, flying aircraft) may have restrictions depending on your symptoms and risk level
• Stay well-hydrated
• Avoid medications that can worsen HCM (your doctor will advise)

What Is the Long-Term Outlook?

With modern treatments and monitoring, most people with HCM can expect a normal or near-normal lifespan. Regular follow-up is essential to:

• Monitor for any changes in your heart
• Adjust treatment as needed
• Detect and manage complications early (irregular heart rhythms, heart failure)

Key message: HCM is a lifelong condition, but with expert care, the vast majority of people live full, active lives.

---

13. Frequently Asked Questions (FAQs)

Q: If I have HCM, will I definitely pass it to my children?

A: If you have a genetic mutation causing your HCM, each child has a 50% (1 in 2) chance of inheriting that mutation. However, even if they inherit the mutation, they may not develop symptoms for many years (or ever, in some cases). Regular screening allows early detection and preventive treatment.

Q: Can HCM be cured?

A: There is currently no cure for HCM. However, treatments are very effective at managing symptoms, reducing obstruction, and preventing complications (including sudden cardiac death). Research into gene therapies is ongoing but not yet available.

Q: I feel completely well—do I really need treatment?

A: Many people with HCM have no symptoms, and some need no specific treatment. However, regular monitoring is essential because HCM can change over time. Your doctor will assess your individual risk of complications and recommend treatment only if needed.

Q: Will I need an ICD (defibrillator)?

A: Only if you are at higher risk of dangerous heart rhythms. Your doctor uses a risk calculator that considers factors like your heart muscle thickness, family history, and other features. Most people with HCM do NOT need an ICD—only those at higher risk.

Q: Can I drink alcohol?

A: Moderate alcohol intake is usually safe. However, excessive alcohol can:

• Trigger irregular heart rhythms (atrial fibrillation, palpitations)
• Cause dehydration (which worsens obstruction)
• Interact with some HCM medications

Discuss safe limits with your doctor.

Q: What is mavacamten, and should I take it?

A: Mavacamten is a new medication (approved 2022) that directly targets the heart muscle problem in HCM. It is used for people with obstruction and symptoms not adequately controlled by standard medications (beta-blockers, etc.). It can:

• Reduce or eliminate obstruction
• Improve breathlessness and exercise capacity
• Potentially avoid the need for surgery/procedures

Your doctor will discuss whether mavacamten is right for you based on your symptoms and heart scan results.

Q: I've read that young athletes die suddenly from HCM. Am I at risk?

A: HCM is the leading cause of sudden cardiac death in young athletes, but this is rare. Most sudden deaths occur in people who didn't know they had HCM. Now that you are diagnosed and under specialist care, your risk is very different:

• Your doctor will assess your individual risk
• You will be monitored regularly
• If you are at higher risk, an ICD provides life-saving protection
• Exercise advice will be tailored to your specific situation

Modern risk stratification is very good at identifying who needs extra protection.

Q: Can HCM get worse over time?

A: HCM can change over time:

• The heart muscle may become slightly thicker with age
• Obstruction may develop or worsen
• Heart rhythm problems (like atrial fibrillation) become more common as you get older
• A small number of people develop heart failure later in life ("burnt-out" HCM)

This is why regular monitoring is important—so changes can be detected and treated early.

---

14. References

1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. PMID: 25814232

2. Marian AJ. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circ Res. 2021;128(10):1533-1553. PMID: 33983830

3. Lopes LR, Ho CY, Elliott PM. Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice. Eur Heart J. 2024;45(30):2711-2724. PMID: 38984491

4. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-1092. PMID: 19221222

5. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015;65(18):1915-1928. PMID: 25936260

6. Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387-1398. PMID: 30297972

7. Arbelo E, Protonotarios A, Gimeno JR, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. PMID: 37622657

8. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. PMID: 32871100

9. Desai MY, Owens A, Geske JB, et al; VALOR-HCM Investigators. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022;80(2):95-108. PMID: 35798458

10. Berge KE, Leren TP. Genetics of hypertrophic cardiomyopathy in Norway. Clin Genet. 2014;85(3):217-220. PMID: 24111713

11. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232-2239. PMID: 17088454

12. Lorenzini M, Norrish G, Field E, et al. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020;76(5):550-559. PMID: 32731933

13. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ Genom Precis Med. 2019;12(2):e002460. PMID: 30759984

14. Pelliccia A, Sharma S, Gati S, et al; ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. PMID: 32860412

15. Wang J, Yang S, Ma X, et al. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines. Eur Heart J. 2023;44(47):4942-4956. PMID: 37795986

16. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003;92(10):1183-1186. PMID: 14609593

17. Jääskeläinen P, Miettinen R, Kärkkäinen P, et al. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med. 2004;36(1):23-32. PMID: 15000344

18. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84(5):476-482. PMID: 11040002

19. Helms AS, Davis FM, Coleman D, et al. Sarcomere mutation-specific expression patterns in human hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2014;7(4):434-443. PMID: 25031304

20. Zou Y, Wang J, Liu X, et al. Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. Mol Biol Rep. 2013;40(6):3969-3976. PMID: 23283745

21. Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617-621. PMID: 26912705

22. Dasari M, Arun Kumar P, Bhattad PB, et al. Yamaguchi syndrome - An updated review article of electrocardiographic and echocardiographic findings. Am J Med Sci. 2023;365(6):505-511. PMID: 37003508

23. O'Mahony C, Jichi F, Pavlou M, et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010-2020. PMID: 24126876

24. Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017;69(7):761-773. PMID: 28209217

25. Norrish G, Ding T, Field E, et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019;4(9):918-927. PMID: 31389933

26. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-1258. PMID: 15837257

27. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470-476. PMID: 16053959

28. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. PMID: 37622656

29. Maron MS, Masri A, Choudhury L, et al. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34-45. PMID: 36609438

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace professional medical judgement. All clinical decisions should be made in consultation with qualified healthcare professionals, considering individual patient circumstances.